Avidity Partners Management LP Kinnate Biopharma Inc. Transaction History

Avidity Partners Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $182,342 - $420,546	-52,700 Reduced 4.35%	1,160,000 $7.25 Million
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $468 - $1,084	89 Added 0.01%	1,212,700 $7.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $12 Million - $19.1 Million	1,212,611 New	1,212,611 $14.5 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.